Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.
- DOI
- 10.1186/s40164-022-00268-z
- Published
- 2022 Mar 25
- Container
- Experimental hematology & oncology
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1186/s40164-022-00268-z,
title = {Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.},
author = {Cartron G and Fox CP and Liu FF and Kostic A and Hasskarl J and Li D and Bonner A and Zhang Y and Maloney DG and Kuruvilla J},
year = {2022},
journal = {Experimental hematology \& oncology},
doi = {10.1186/s40164-022-00268-z},
url = {https://doi.org/10.1186/s40164-022-00268-z}
}RIS
TY - JOUR TI - Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel. AU - Cartron G AU - Fox CP AU - Liu FF AU - Kostic A AU - Hasskarl J AU - Li D AU - Bonner A AU - Zhang Y AU - Maloney DG AU - Kuruvilla J PY - 2022 JO - Experimental hematology & oncology DO - 10.1186/s40164-022-00268-z UR - https://doi.org/10.1186/s40164-022-00268-z ER -
APA
G, C., CP, F., FF, L., A, K., J, H., D, L., A, B., Y, Z., DG, M., & J, K. (2022). Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleucel versus tisagenlecleucel.. Experimental hematology & oncology. https://doi.org/10.1186/s40164-022-00268-z
Source records
- pubmed · retrieved 2026-09-26T08:57:18.644Z